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Abstract  
Impaired metabolism may play an important role in the pathogenesis of lethal prostate cancer, 
yet there is a paucity of evidence regarding the association. We conducted a large prospective 
serum metabolomic analysis of lethal prostate cancer in 523 cases and 523 matched controls 
nested within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Median 
time from baseline fasting serum collection to prostate cancer death was 18 years (maximum 30 
years). We identified 860 known biochemicals through an ultrahigh-performance LC-MS/MS 
platform. Conditional logistic regression models estimated odds ratios (OR) and 95% confidence 
intervals of risk associated with 1-standard deviation (s.d.) increases in log-metabolite signals. 
We identified 34 metabolites associated with lethal prostate cancer with a false discovery rate 
(FDR)<0.15. Notably, higher serum thioproline, and thioproline combined with two other 
cysteine-related amino acids and redox metabolites, cystine and cysteine, were associated with 
reduced risk (1-s.d. OR=0.75 and 0.71, respectively; P≤8.2×10-5). By contrast, the dipeptide 
leucylglycine (OR=1.36, P=8.2×10-5), and three gamma-glutamyl amino acids (OR=1.28-1.30, 
P≤4.6×10-4) were associated with increased risk of lethal prostate cancer. Cases with metastatic 
disease at diagnosis (N=179) showed elevated risk for several lipids, including especially the 
ketone body 3-hydroxybutyrate (BHBA), acyl carnitines, and dicarboxylic fatty acids 
(1.37≤OR≤1.49, FDR<0.15). These findings provide a prospective metabolomic profile of lethal 
prostate cancer characterized by altered biochemicals in the redox, dipeptide, pyrimidine, and 
gamma-glutamyl amino acid pathways, whereas ketone bodies and fatty acids were associated 
specifically with metastatic disease.  
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What’s New? 
The associations between serum metabolites and risk of lethal prostate cancer (LPC) years in 
advance of diagnosis were examined using untargeted mass-spectrometry-based metabolomics. 
Increased oxidative stress-related thioproline and two other cysteine-related metabolites were 
prominently associated with lower LPC risk. By contrast, dipeptides including leucylglycine, and 
several gamma-glutamyl amino acids, were related to elevated risk. This prospective molecular 
pattern points to a role for redox and peptide metabolism in LPC, and provides potential leads 
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Introduction 
Prostate cancer accounts for a large worldwide health burden among men for both incidence and 
mortality, yet there are no established etiologic factors beyond older age, family history, low 
penetrance genetic variants, and African ancestry race. The widespread use of prostate-specific 
antigen (PSA) testing during the past 25 years has led to over-diagnosis and overtreatment of 
indolent, microscopic adenocarcinomas with resulting clinical consequences.1 Therefore, among 
the challenges in studying prostate cancer etiology is identification of men at higher risk of 
developing clinically aggressive disease that is fatal. Recent improvements in metabolomic 
technologies have enabled comprehensive assessment of hundreds and thousands of circulating 
metabolites that reflect biochemical activity, regulation and dysregulation.2 Systematic 
prospective examination of altered metabolites of lethal prostate cancer cases prior to clinical 
onset may help identify unique metabolic traits that are potential early markers of dysregulated 
biochemical pathways associated with disease risk or progression.3 
Few prospective studies have examined pre-diagnostic metabolites in relation to prostate 
cancer risk.4-8  In our previous prospective metabolomic study of 625 metabolites measured in 
200 cases and 200 controls nested within the Alpha-Tocopherol, Beta-Carotene Cancer 
Prevention (ATBC) Study, nominal inverse associations between serum energy and lipid 
metabolites and aggressive prostate cancer risk were observed.5 A similar metabolomics analysis 
of 1,077 cases and 1,077 controls in the European Prospective Investigation into Cancer and 
Nutrition (EPIC) study that identified 122 metabolites also showed 12 glycerophopholipids 
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inversely associated with advanced prostate cancer risk (208 cases), with some nominal 
associations for lethal disease based on 127 cases.8 Our aim here was to identify pre-diagnostic 
serum metabolites associated with lethal prostate cancer risk in an unscreened population.  
Methods 
Study population 
The ATBC Study was a randomized, 2×2 factorial, double-blinded, placebo-controlled primary 
prevention trial to examine whether supplementation of alpha-tocopherol (50 mg/day), beta-
carotene (20 mg/day), or both could reduce cancer incidence. From 1985 to 1988, the ATBC 
Study enrolled 29,133 male Caucasian smokers, aged 50-69 years, from southwestern Finland. 
Details of the trial have been previously described.9 The trial ended on April 30, 1993, and since 
that time, all participants have been followed through linkage with the Finnish Cancer Registry 
and Register of Causes of Death. Pre-supplementation overnight fasting blood samples from all 
participants were collected following a standard operating procedure at their enrollment. 
Demographic characteristics, medical history, and behavioral and lifestyle factors were collected 
via self-reported questionnaires at enrollment. Height and weight were measured by professional 
study personnel.9 Baseline serum concentrations of retinol and alpha-tocopherol were measured 
using an isocratic high-performance liquid chromatography (HPLC) platform.10  
Case ascertainment and control selection 
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Prostate adenocarcinoma cases (N=523) diagnosed through December 31, 2014, were identified 
based on the International Classification of Diseases (ICD) 9th revision, code 185. Selection was 
limited to cases who died of prostate cancer (ICD-9=185 or ICD-10=C61; subsequently referred 
to as “lethal prostate cancer”). Lethal cases with metastatic disease were defined as those with 
distant metastasis (M1) at clinical diagnosis. Using incidence-density sampling without 
replacement, 523 controls were selected from the cohort who were alive and cancer-free at the 
time of prostate cancer case death and individually matched to cases by age (± 1 year) and date 
of baseline blood collection (± 30 days).  
Metabolite profiling 
We used a high-resolution accurate mass (HRAM) platform, namely ultrahigh-performance 
liquid chromatography/tandem mass spectrometry (LC-MS/MS) at Metabolon Inc., to conduct 
serum metabolite profiling. All metabolite identifications were based on multiple orthogonal 
criteria to a mass spectral library built from authentic standards, namely tier 1 identification.11, 12 
We measured 1,170 metabolites; we included 860 identified metabolites in further analysis, after 
excluding unknown metabolites or metabolites for which fewer than 10% of participants had 
detectable values (Supplementary Table S1). Missing values were imputed to one-half the 
minimum detectable metabolite value. The identified metabolites were categorized into eight 
chemical classes: amino acids and amino acid derivatives (subsequently refer to as “amino 
acids”), carbohydrates, cofactors and vitamins, energy metabolites, lipids, nucleotides, peptides 
or xenobiotics, that are adapted according to the Kyoto Encyclopedia of Genes and Genomics 
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(KEGG) database, as well as Human Metabolome Database (HMDB) (Supplementary Table 
S1). We calculated the Coefficients of Variations (CVs) and Intraclass Correlation Coefficients 
(ICCs) for each metabolite prior to log-transformation using 16 or 18 replicate samples from 4 
unique ATBC individuals (66 total QC samples), to examine reliability and reproducibility of the 
metabolite data. 
Serum retinol and alpha-tocopherol concentrations identified by metabolomics were 
highly correlated with concentrations quantified for the cohort earlier using an isocratic HPLC 
method, supporting good laboratory validity and reproducibility for the present metabolomics 
platform (retinol: r=0.90, P=10-214; alpha-tocopherol: r=0.79, P<10-214; Supplementary Figures 
S1 and S2). 
Statistical analysis 
Baseline characteristics of lethal prostate cancer cases and controls were compared by either the 
Wilcoxon rank sum or χ2 test. All the metabolites were log-transformed and standardized 
(mean=0 and variance=1). Conditional logistic regression was used to estimate odds ratios (OR) 
and 95% confidence intervals (CIs) for a 1-standard deviation (s.d.) increase in log-metabolite 
level on the risk of lethal prostate cancer. The unadjusted model inherently conditions on the 
matching factors. Sensitivity analyses also adjusted for body mass index (BMI), number of 
cigarettes smoked per day, baseline serum concentrations of total cholesterol, high-density 
lipoprotein (HDL) cholesterol, alpha-tocopherol, and retinol, and fasting hours (as continuous 
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variables), and ATBC intervention group (as a categorical variable). Adding any of these 
covariates in the model did not change the risk estimate of metabolite by 10% or more; therefore, 
we present results from the unadjusted conditional models. We assessed if the metabolite-
prostate cancer relationships differed based on lower/higher BMI (<26 or ≥26 kg/m2), and time 
between blood collection and prostate cancer death (≤18 or >18 years) by including the cross-
product term between the dichotomous variable (BMI or time) and the log-metabolite level in the 
regression. We also examined the metabolite-lethal prostate cancer associations within the first 
10 years from serum collection to prostate cancer death. Based on the Benjamini-Hochberg 
method, we used a false discovery rate (FDR, q-value) <0.15 to present the metabolite-risk 
associations.  
We used Gene-Set Analysis (GSA) to estimate whether the pre-defined metabolic 
chemical classes and sub-classes (subsequently referred to as super- or sub-pathways) were 
related to lethal prostate cancer risk.13 Briefly, allowing {Z1,…, Zs} of the Z values from testing 
the S metabolites in a pre-defined pathway, GSA calculates the “maxmean” statistics max (+Z+, -
Z-), that +Z+(-Z-) is the mean of all positive (negative) values.13 We calculated the P-values for 
each pathway by 105 permutations. For each pathway that was associated with lethal prostate 
cancer, we performed principal component analysis (PCA, using the varimax rotation method) 
and defined a “pathway score” as the first principal component. We further assessed whether the 
pathway score was associated with lethal prostate cancer using conditional logistic regression.  
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Thioproline and cystine have been reported as direct metabolites of cysteine in in vivo 
experiments,14 and cysteine-related metabolites play an important role in modulating redox status 
that may be related to risk of lethal prostate cancer. We therefore examined whether 
combinations of these cysteine-related metabolites (thioproline, cysteine, and cystine) were 
associated with risk of lethal prostate cancer by calculating the sum of the standardized 
metabolite values weighted by their corresponding beta coefficients from the conditional logistic 
regression analyses. We then entered the weighted sum value into a separate conditional logistic 
regression model. 
We also examined metabolite-lethal prostate cancer associations comparing all controls 
with subgroups of men defined by having been diagnosed with or without metastases, using 
unconditional logistic regression models adjusted for age at blood collection, date of baseline 
blood collection, and time interval from blood collection to cancer diagnosis (or, for controls, to 
cancer diagnosis date of the matched case).  
We created Gaussian graphical models to summarize relationships among metabolites in 
the pathways associated with lethal prostate cancer risk. Gaussian graphical models include 
edges between pairs of metabolites with a partial correlation coefficient, conditioned on other 
metabolites, less than -0.2 or greater than 0.2 from the analysis.15, 16  
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All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC), and R 
version 3.4.0 (R Development Core Team, Vienna, Austria). All the reported statistical tests 
were two-sided. 
Results 
Table 1 presents baseline characteristics of the study population. Cases were similar to controls 
with the exception of having a higher prevalence of prostate cancer family history. Median time 
from serum collection to prostate cancer death was 18 years (inter-decile range= 9.6 to 26 years). 
The median metabolite ICC and CV were 0.88 (interquartile range=0.68 to 0.95) and 0.20 
(interquartile range=0.12 to 0.37), respectively. 
Using conditional logistic regression models, we found thirty-four out of 860 identified 
serum metabolites associated with lethal prostate cancer risk at an FDR<0.15 (Table 2), 
including 9 amino acids, 1 cofactor/vitamin, 7 lipids, 5 nucleotides, and 12 peptides (Table 2). 
The two strongest associations were the dipeptide leucylglycine (per 1-s.d., OR=1.36, 
P=8.19×10-5, FDR=0.029) and amino acid derivative thioproline (OR=0.75, P=8.23×10-5, 
FDR=0.029) (Table 2). We also found three gamma-glutamyl amino acids yielded strong 
positive association signals for lethal prostate cancer: gamma-glutamylvaline, gamma-
glutamylglycine and gamma-glutamylleucine (per 1-s.d., ORs=1.28-1.30, 2.60×10-4≤P≤4.58×10-
4, FDR=0.061-0.064). Several other dipeptides such as histidylalanine, valylglycine and 
leucylglutamine, as well as the uracil pyrimidines pseudouridine, 2'-O-methyluridine, 5,6-
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dihydrouridine and 5-methyluridine, had positive associations with lethal disease (Table 2). We 
observed inverse associations for three fibrinogen cleavage peptides, and the top lipid signals 
were eicosanoid 5-HEPE, androgenic steroid androstenediol (3beta,17beta) disulfate, and 
glycerol (OR=1.21-1.25, 0.0014≤P≤0.0043) (Table 2). These results remained unchanged after 
additional adjustment for potential confounding factors (Supplementary Table S2).  
Only thioproline showed effect modification by latent time (P=0.002 and FDR q-value 
=0.055 for interaction), with a stronger lethal prostate cancer association observed within 18 
years of serum collection (Supplementary Figure S3). No metabolite was significantly 
associated with lethal prostate cancer risk at an FDR of <0.15 when we restricted follow-up time 
to less than 10 years from serum collection to prostate cancer death; however, there were only 59 
case-control sets in that early period (all FDR q-value>0.6, Supplementary Table S3). 
Stratification based on baseline BMI below and above the median of 26 kg/m2 revealed that 
associations with N-acetylserine, 1-linoleoyl-GPC (18:2) and pseudouridine were stronger 
among individuals with lower BMI, whereas dihydroorotate and 2'-O-methyluridine were more 
prominently associated in overweight and obese men (interaction P-values=0.04-0.09; all FDR 
q-values≥0.60 and lack of statistical significance).  
Based on Pearson correlation coefficients, a correlation heat-map of the metabolites 
associated with lethal prostate cancer is shown in Figure 1. Higher positive correlations were 
seen within the fibrinogen cleavage peptide and gamma-glutamyl amino acid chemical sub-
classes.   
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 GSA identified an association between lethal prostate cancer and the peptide class 
pathway (P<0.0001). The analysis also identified associations with chemical sub-classes for 
dipeptides, uracil-containing pyrimidines, gamma-glutamyl amino acids, 
glycine/serine/threonine, polyunsaturated fatty acids (n3 and n6), aminosugars, androgenic 
steroids, dicarboxylate fatty acids, and endocannabinoids (FDR≤0.1, Table 3). In the PCA 
analysis, the first principal components of metabolites in pathways of dipeptide, uracil-
containing pyrimidine, gamma-glutamyl amino acid, glycine/serine/threonine, polyunsaturated 
fatty acid (n3 and n6), aminosugar, and endocannabinoid metabolism, were positively associated 
with overall lethal prostate cancer risk, representing 10% to 36% risk in increment per 1-s.d. 
pathway-score increase in the log-scale (FDR<0.15, Table 3). In the selected chemical sub-
classes, the interconnected networks built with Gaussian graphical models for metabolites with 
conditional correlations (r ≤-0.2 or ≥0.2) are represented in Figure 2. We then repeated the GSA 
in subsets stratified by time between baseline and prostate cancer death.  Similar results were 
obtained in the analysis focused on cases diagnosed within 18 years of blood collection 
(FDR<0.15, Table 3), but associations were weaker among cases diagnosed more than 18 years 
after baseline blood collection (FDR≥0.32, Table 3).  
Conditional logistic regression models of serum cysteine-related metabolites on a 
continuous scale showed ORs of 0.71-0.80 for lethal prostate cancer risk per 1-s.d. increment on 
the log-scale (P=1.10×10-5-0.0040; Table 4). Men in the top quartile of these amino acids were 
at 27%-47% reduced risk, compared to those in the lowest quartile (Table 4). Results were 
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similar after adjustment for potential confounding factors (Table 4). The combined cysteine 
related-metabolites stratified by time from serum collection to prostate cancer death revealed 
stronger associations within 18 years (Supplementary Table S4).  
 Unconditional logistic regression models of metastatic disease (179 cases diagnosed with 
metastatic prostate cancer and who subsequently died from their disease) showed that 17 out of 
860 identified serum metabolites were associated with risk of fatal prostate cancer in men with 
metastatic disease at diagnosis at an FDR<0.15 (Table 5), including two amino acids, 13 lipids, a 
nucleotide and a peptide. We observed higher risk for several elevated lipids, including the 
ketone body 3-hydroxybutyrate (BHBA), acyl carnitines hexanoylglycine and 3-
hydroxybutyroylglycine and acetoacetate, dicarboxylate fatty acid 3-methyladipate, N-
acetylglycine, and pimeloylcarnitine/3-methyladipoylcarnitine (per 1-s.d., 1.37≤OR≤1.49, 
FDR<0.15) (Table 5). The lysophospholipid 1-linoleoyl-GPC (18:2) was inversely associated 
(OR≤0.76, FDR<0.15; Table 5). Other acyl carnitines and dicarboxylic and monohydroxy fatty 
acids were similarly associated with metastatic disease (FDR<0.15; Table 5), and of 88 
metabolites associated at P<0.05, 56 were lipids. By contrast, the risk associations among the 
213 cases without metastases at diagnosis were inverse with fibrinogen cleavage peptides, two 
amino acids, and 2'-O-methylcytidine (per 1-s.d., 0.68≤OR≤0.73, FDR<0.15; Supplementary 
Table S5). At the nominal P<0.05 threshold, only 6 serum lipids out of 69 metabolites were 
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To the best of our knowledge, this is the largest prospective metabolomic analysis of lethal 
prostate cancer to date. With an average time from blood collection to prostate cancer death of 
18 years, 34 serum metabolites in multiple biochemical pathways were associated with lethal 
disease. We found oxidative stress-related thioproline, and its combination with two other 
cysteine-related metabolites, as top molecular species inversely associated with risk. By contrast, 
serum dipeptides including leucylglycine, as well as several gamma-glutamyl amino acids, were 
associated with higher risk of lethal prostate cancer. Cases with metastatic disease at diagnosis 
showed strong associations with elevated fatty acid metabolites and ketone bodies. 
 The inverse associations we observed between lethal prostate cancer and serum 
thioproline, cysteine, and cystine, which appeared stronger in the first 18 years of follow-up, are 
consistent with experimental evidence.17-20 Given the fact that metabolomic data are scant for 
fatal prostate cancer, we examined the cysteine-related metabolic score in 298 aggressive 
prostate cancers (cancer stage III/IV at diagnosis based on the tumour-node-metastasis staging 
system, or a tumor Gleason score ≥8) and their matched controls from a previously published 
analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)7 and 
found a 1-SD increment ORaggressive prostate cancer of 0.91 (95% CI: 0.75, 1.11, P=0.35). Further, 
examining only aggressive cases diagnosed within 8 years of blood collection (N=64) showed a 
stronger association for the cysteine-related metabolic score (1-SD, ORaggressive prostate cancer= 0.74, 
95% CI: 0.50-1.12, P=0.16), a finding essentially consistent with the present analysis, and 
supportive of a role for alterations in redox metabolism in prostate cancer etiology or early 
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detection. Thioproline, or thiazolidine-4-carboxylic acid, is a cyclic sulfur amino acid and 
condensation product of cysteine and formaldehyde,21 that, along with cysteine, functions as an 
intracellular sulfhydryl antioxidant and free radical scavenger to reduce cellular membrane and 
organelle oxygen-radical damage of relevance to carcinogenesis.22 Genetic alterations and rapid 
cell proliferation resulting in greater oxidative stress from reactive oxygen species (ROS) have 
been reported in various cancers, including prostate cancer.18 As the biosynthetic precursor of 
intracellular glutathione (GSH), the extracellular cysteine pool including its disulfide form, 
cystine, can act as a redox buffer that tumor cells require to maintain an adequate antioxidant-
redox balance.19, 23 For example, experimental data show that cyst(e)inase treatment results in 
sustained depletion of extracellular cysteine and prostate carcinoma allograft growth 
suppression.20  
We identified several gamma-glutamyl peptides and dipeptides directly related to 
increased lethal prostate cancer risk. Gamma-glutamylpeptidase (GGT) liberates free gamma-
glutamyl peptides through the breakdown of glutathione and is a clinical indicator of chronic 
liver disease.24 Circulating gamma-glutamyl peptides have been associated with risk of 
hepatocellular carcinoma,24 and studies showed that elevated serum GGT is related to higher risk 
of overall and site-specific cancers, including prostate cancer.25, 26 Collectively, data from prior 
studies provide evidence that redox imbalance and peptide metabolism impact prostate 
tumorigenesis, and data from the present study support such a role in lethal disease specifically.  
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 The serum pyrimidines pseudouridine, 5,6-dihydrouridine, 2'-O-methyluridine and 5-
methyluridine were elevated in cases compared to their matched control subjects, and the overall 
pathway showed a strong association. Pseudouridine is a modified nucleoside generated from the 
degradation of transfer RNA (tRNA), and previous studies have demonstrated elevated levels of 
modified nucleosides, particularly pseudouridine, in the biological fluids of cancer patients when 
compared with cancer-free controls.27, 28 Dihydrouridine is one of the most common 
modifications of tRNA and has been related to cancer,29, 30 cancer cell growth and survival.30  
Our data also showed that serum dihydroorotate was inversely associated with lethal prostate 
cancer risk. Dihydroorotate dehydrogenase (DHODH), localized to the mitochondrial 
membranes, catalyzes the conversion of dihydroorotate to orotate, leading to de novo pyrimidine 
biosynthesis which may facilitate tumor growth. A recent tissue-based RNA expression analysis 
provided evidence supporting a role for pyrimidine metabolism in prostate cancers.31 
 Dysregulation of lipid metabolism and particularly alterations in fatty acids have been 
increasingly recognized to influence carcinogenesis. Only a few serum lipids were positively 
associated with lethal prostate cancer in our study, including polyunsaturated fatty acids, 
androgens, and the eicosanoid 5-HETE. Notwithstanding laboratory-based data that 
eicosapentaenoic acid may suppress prostate carcinogenesis, we found that the polyunsaturated 
fatty acid (n3 and n6) pathway was associated with increased risk (as were androgenic steroids), 
consistent with previous population-based studies.7, 32 The inflammatory biomarker 5-HETE, a 
metabolic product of arachidonic acid concentrated in prostate adenocarcinoma tissue,33 was also 
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related to higher risk of lethal prostate cancer, consistent with previously observed increased 
prostate cancer cell proliferation34 and reduced apoptosis.35 
Importantly, we observed a strong lipid-dominant metabolomic profile of lethal 
metastatic disease, including elevated ketone bodies (BHBA), and acyl glycine/acyl carnitine, 
dicarboxylic and monohydroxy fatty acids, and lower serum lysophospholipid 1-linoleoyl-GPC 
(18:2). Alterations of BHBA potentially drive tumor progression and metastasis,36 and higher 
circulating BHBA has been associated with other cancers including liver, esophagus, ovary and 
endometrium.37-40 The higher circulating fatty acids we identified in cases with metastatic 
disease could indicate de novo biosynthesis or lipolytic triglyceride mobilization of fatty acids in 
response to the increased membrane lipid bilayer and cell proliferation requirements of these 
aggressive cancers.41-43 Upregulated fatty acid biosynthesis is also critical for increased 
acylcarnitine beta-oxidation for mitochondrial ATP production.41, 44 
 In addition to the present study nested within the ATBC cohort, five prospective studies 
of metabolites and prostate cancer risk have been published, including two others nested within 
the ATBC study,4, 5 and one each in the EPIC study,8 EPIC-Heidelberg,6 and PLCO.45 The 
reported metabolomic profiles of risk differ considerably among these studies, probably as a 
result of differences in parent study designs (including cancer screening and fasting status), 
sample sizes, source populations, assay platforms, and time from blood collection to cancer 
diagnosis (or death). For example, in the five prior studies, the control participants were selected 
from among those who were alive and free of cancer at the time of diagnosis of the case, whereas 
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controls in the present study were selected based on vital status and being free of cancer at the 
time of prostate cancer death. In addition, the EPIC study was the only other one to report on 
fatal prostate cancer risk. This study included only 127 fatal cases and 122 measured metabolites 
(of which >60% were glycerophospholipids), however, as compared with the present analysis of 
523 fatal prostate cancers and 860 metabolites representing eight chemical class pathways. The 
metabolomic profile of primarily non-lethal disease in previous studies showed nominal 
associations for lipids, and TCA cycle and amino acid metabolites, including especially 
glycerophospholipids, inositols and sphingomyelins.4-8 For example, of the several 
glycerophopholipids we originally found associated with aggressive prostate cancer in this same 
cohort,5 only 1-linoleoyl-GPC (18:2) was related to lethal disease in the present analysis (and in 
the same association direction). The nested case-control subset analysis of 127 fatal prostate 
cancers in EPIC study found seven metabolites nominally associated with lethal disease.8 Only 
two of these (methionine and trans-4-hydroxyproline) were identified in the present study, 
however, and no significant associations were found. On the other hand, there was one 
metabolite identified in our study [acetylcarnitine (C2)] that is closely related to the 
acetylcarnitine (C3) identified in the EPIC study that showed a similar increased risk of fatal 
prostate cancer (OR=1.68, 95% CI: 1.14, 2.49, P=0.009). This compares with the present 
findings for acetylcarnitine (C2): OR=1.17, 95% CI: 1.03, 1.33, P=0.014 (overall analysis, data 
not shown); for follow-up time ≤10 years from serum collection to prostate cancer death, 
OR=1.54, 95% CI: 1.05, 2.25, P=0.028 (Supplementary Table S3). 
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 Strengths of our investigation include its relatively large sample size and that metabolites 
were measured in serum collected up to three decades prior to prostate cancer death. 
Ascertainment of lethal cases was from census-based Finnish population cancer and mortality 
registries with complete follow-up and high accuracy. Using an untargeted approach with good 
laboratory validity and reproducibility, we were able to identify nearly 900 metabolites 
representing a large number of biochemical pathways. Limitations of this study deserve 
consideration, including that the homogenous nature of the male smoker population of European 
ancestry may limit generalizability of our findings to other populations, and the lack of 
validation from an external study. Our metabolomic profile was of single serum samples 
collected at baseline, and assays of two or more samples from the same individual at different 
time points may have provided more accurate metabolite estimates. Measurement error may exist 
for the metabolomic profile measurement. It is important to point out, however, that any such 
misclassification should be nondifferential between metabolite measurement groups and would 
theoretically only influence our findings toward the null. The extensive panel of metabolites 
identified by the HRAM platform is advantageous for discovery, but at the same time precluded 
our ability to validate the findings because of the large number of metabolites not measured in 
other studies. Finally, although we adjusted for potential confounding factors in the sensitivity 
analyses, unmeasured or residual confounding remains possible. 
In conclusion, this study identified a novel serum metabolite profile up to three decades 
prior to prostate cancer death that is characterized by multiple altered biochemicals in redox, 
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dipeptide, pyrimidine and gamma-glutamyl amino acid pathways. Of note, as the stronger 
inverse association of the redox metabolites within the first 18 years suggested reverse causality, 
it may be supportive of a role for alterations in redox metabolism in prostate cancer early 
detection. The observed profile differs from prior smaller studies that included cases of non-
aggressive and aggressive disease that were predominantly not fatal. Men diagnosed with 
metastatic disease prospectively showed a prominent lipid profile comprised of ketone bodies 
and fatty acids. Our findings warrant both re-examination in other prospective studies and 
investigation of the underlying pathogenic molecular mechanisms. 
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Figure legends 
Figure 1. A heat map of correlation coefficients among metabolites associated with lethal 
prostate cancer. The colors represent the association directions of Pearson correlation 
coefficients, with red indicating positive correlations, and blue indicating negative correlations. 
Magnitudes of the correlation coefficients are represented by both numerical percents and circle 
sizes (i.e., larger circles for stronger correlations). 
Figure 2. Gaussian graphical model of metabolites in the chemical sub-class pathways most 
related to lethal prostate cancer risk in the study. Metabolites are drawn as hexagons, and the 
pairs with an absolute value of conditional correlation ≥0.2 are connected by a line. The colors 
represent the association directions of conditional correlations, with pink indicating positive 
conditional correlations, and blue indicating negative conditional correlations. Magnitude of the 
conditional correlations are represented by line width (i.e., wider lines for stronger correlations). 
Hexagons are color-labelled by their associations with lethal prostate cancer (p-value <0.05), 
with pink indicating a positive association with lethal disease, with blue indicating an inverse 
association. Metabolites with an asterisk indicates that the association with an FDR<0.15. ATBC, 
Alpha-Tocopherol, Beta-Carotene Cancer Prevention. 
 
Supplementary Table legends 
Supplementary Table S1. List of measured known metabolites 
Supplementary Table S2. Multivariate adjusted ORs and 95% CIs (per 1-s.d.) from conditional 
logistic regression for the association between lethal prostate cancer risk and serum metabolites 
based on 523 case-control pairs in the ATBC Study.  Models were adjusted for body mass index, 
number of cigarettes per day, baseline serum total cholesterol, HDL cholesterol, alpha-
tocopherol, and retinol, and ATBC intervention group. 
Supplementary Table S3. ORs and 95% CIs (per 1-s.d.) from conditional logistic regression for 
the association between lethal prostate cancer risk and serum metabolites according to follow-up 
time from serum collection to prostate cancer death (≤10 years) with the P-value<0.05 based on 
59 case-control pairs in the ATBC Study  
Supplementary Table S4. ORs and 95% CIs from conditional logistic regression for lethal 
prostate cancer associated with combined serum cysteine related-metabolites stratified by time 
between blood collection and prostate cancer death, in the ATBC Study 
Supplementary Table S5. ORs and 95% CIs from unconditional logistic regression (per 1-s.d.) 
for the association between serum metabolites and lethal prostate cancer without metastasis at 
diagnosis in the ATBC Study 
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Supplementary Figure legends 
Supplementary Figure S1. Scatter plot of baseline serum retinol independently measured from 
two platforms: isocratic HPLC platform at a Finnish laboratory (certified by a National Institute 
of Standards and Technology quality-control testing program) and a HRAM platform of 
ultrahigh-performance LC-MS/MS at Metabolon Inc. HPLC, high-performance liquid 
chromatography; HRAM, high-resolution accurate mass; LC, liquid chromatography; MS, mass 
spectrometry   
Supplementary Figure S2. Scatter plot of serum alpha-tocopherol independently measured 
from two platforms: isocratic HPLC platform at a Finnish laboratory (certified by a National 
Institute of Standards and Technology quality-control testing program) and a HRAM platform of 
ultrahigh-performance LC-MS/MS at Metabolon Inc. HPLC, high-performance liquid 
chromatography; HRAM, high-resolution accurate mass; LC, liquid chromatography; MS, mass 
spectrometry 
Supplementary Figure S3. ORs and 95% CIs (per 1-s.d.) from conditional logistic regression 
for the association between lethal prostate cancer risk and serum metabolites according to 
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Table 1. Baseline characteristics of the cases and controls in the ATBC Study a 
 Cases  Controls P-value 
N 523 523 Matched 
Age at blood collection, years 57.9 (5.0) 57.4 (4.8) Matched  
Height (cm) 173.9 (6.2) 173.7 (6.2) 0.59 
Weight (kg) 79.4 (12.6) 79.6 (12.9) 0.90 
BMI (kg/m2) 26.2 (3.6) 26.3 (3.8) 0.59 
History of diabetes (%) 2.1  2.1  1.00 
Physically active (%) 20.5 20.2 0.94 
Cigarettes per day 19.3(8.7) 19.1(8.0) 0.87 
Years of cigarette smoking 35.6 (8.8) 35.9 (8.6) 0.58 
Family history of prostate cancer (%) 6.6 2.3 0.005 
Serum total cholesterol (mmol/L) 6.3 (1.2) 6.3 (1.1) 0.77 
Serum HDL cholesterol (mmol/L) 1.2 (0.3) 1.2 (0.3) 0.59 
Serum alpha-tocopherol (mg/L) 11.9 (3.0) 12.1 (2.9) 0.16 
Serum beta-carotene (µg/L) 231 (189) 234 (195) 0.94 
Serum retinol (µg/L)  602 (131) 590 (117) 0.19 
Dietary intake per day    
Total energy (kcal) 2745 (783) 2713 (729) 0.72 
Fruit (g) 136 (105) 129 (103) 0.27 
Vegetables (g) 116 (74) 112 (63) 0.94 
Red meat (g) 69.8 (33.8) 69.0 (31.6) 0.84 
Coffee (g) 626 (349) 620 (377) 0.59 
Alcohol (ethanol, g) 16.7 (21.8) 15.9 (19.3) 0.74 
Supplement use    
Vitamin A (%) 12.1 9.9 0.27 
Vitamin D (%) 6.9 7.4 0.81 
Calcium (%) 10.0 11.8 0.37 
Clinical characteristics of cases    
Calendar year of diagnosis, No. (%)    
1988-1992 47 (9.1) --  
1993-1997 155 (30.0) --  
1998-2002 149 (28.8) --  
2003-2007 96 (18.6) --  
2008-2014 70 (13.5) --  
Unknown 6   
Cancer stage at prostate cancer diagnosis, No. (%)    
I 76 (17.4) --  
II 109 (24.9) --  
III 55 (12.6) --  
IV 198 (45.2) --  
Unknown 85   
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Mean survival time since diagnosis, years 4.6 --  
Mean follow-up time since blood collection to prostate 
cancer death, years 
18 --  
Number of cases with metastatic disease at diagnosis 179 --  
Abbreviations: ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention, HDL = high-density 
lipoprotein 
a Values are means and standard deviations unless otherwise indicated.
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Table 2. ORs and 95% CIs (per 1-s.d.) from conditional logistic regression for the association between lethal prostate cancer risk and serum 
metabolites achieving the FDR<0.15 threshold based on 523 case-control pairs in the ATBC Study a 
Metabolite b Sub-class pathway Detectable 
values in 
% of the 
study 
population 
OR c 95% CI P-value Q-value P for 
Chemical 
Class d 
Amino acids and amino acid 
derivatives  
      0.063 
Glutamine Glutamate metabolism 100 0.80 0.69, 0.93 0.0033 0.12  
Cysteinylglycine disulfide Glutathione metabolism 100 0.81 0.70, 0.93 0.0032 0.12  
N-Acetylserine Glycine, serine and threonine metabolism 100 1.24 1.07, 1.44 0.0043 0.12  
N-Acetylhistidine Histidine metabolism 100 1.22 1.06, 1.40 0.0048 0.12  
Thioproline  Methionine, cysteine, SAM and taurine 
metabolism 
100 0.75 0.65, 0.86 8.2×10-5 0.029  
Cystine Methionine, cysteine, SAM and taurine 
metabolism 
100 0.80 0.70, 0.91 0.00086 0.088  
Cysteine Methionine, cysteine, SAM and taurine 
metabolism 
100 0.80 0.68, 0.93 0.0044 0.12  
C-Glycosyltryptophan Tryptophan metabolism 100 1.21 1.06, 1.38 0.0038 0.12  
4-Hydroxyphenylpyruvate Tyrosine metabolism 98 0.81 0.71, 0.92 0.0013 0.093  
Cofactors and vitamins       0.76 
Oxalate (ethanedioate) Ascorbate and aldarate metabolism 100 0.83 0.73, 0.95 0.0047 0.12  
Lipids       0.12 
Androstenediol (3beta,17beta) 
disulfate (2) 
Androgenic steroids 100 1.22 1.08, 1.39 0.0021 0.093  
5-HEPE Eicosanoid 57 1.25 1.09, 1.43 0.0014 0.093  
Oleoyl ethanolamide Endocannabinoid 100 1.21 1.05, 1.38 0.0067 0.14  
3-Methyl adipate Fatty acid, dicarboxylate 99 1.20 1.06, 1.36 0.0047 0.12  
Glycerol Glycerolipid metabolism 100 1.21 1.06, 1.38 0.0043 0.12  
3-Hydroxybutyrate (BHBA) Ketone bodies 100 1.19 1.05, 1.34 0.0062 0.14  
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1-Linoleoyl-GPC (18:2) Lysophospholipid 100 0.83 0.72, 0.95 0.0066 0.14  
Nucleotides       0.028 
Dihydroorotate Pyrimidine metabolism, orotate containing 98 0.83 0.72, 0.94 0.0053 0.12  
Pseudouridine Pyrimidine metabolism, uracil containing 100 1.24 1.08, 1.42 0.0017 0.093  
2'-O-Methyluridine Pyrimidine metabolism, uracil containing 100 1.21 1.07, 1.37 0.0023 0.093  
5,6-Dihydrouridine Pyrimidine metabolism, uracil containing 100 1.21 1.06, 1.37 0.0038 0.12  
5-Methyluridine (ribothymidine) Pyrimidine metabolism, uracil containing 100 1.21 1.06, 1.38 0.0038 0.12  
Peptides       <0.0001 
Leucylglycine Dipeptide 38 1.36 1.17, 1.58 8.2×10-5 0.029  
Histidylalanine Dipeptide 25 1.29 1.11, 1.49 0.0010 0.090  
Valylglycine Dipeptide 51 1.23 1.08, 1.41 0.0022 0.093  




Fibrinogen cleavage peptide 98 0.79 0.69, 0.91 0.00088 0.088  
Fibrinopeptide A (5-16) Fibrinogen cleavage peptide 99 0.81 0.71, 0.92 0.0017 0.093  
Fibrinopeptide A, des-ala 
(DSGEGDFXAEGGGVR) 
Fibrinogen cleavage peptide 100 0.81 0.71, 0.93 0.0022 0.093  
Gamma-glutamylvaline Gamma-glutamyl amino acid 100 1.30 1.13, 1.50 0.00026 0.061  
Gamma-glutamylglycine Gamma-glutamyl amino acid 100 1.28 1.11, 1.47 0.00044 0.064  
Gamma-glutamylleucine Gamma-glutamyl amino acid 100 1.29 1.12, 1.48 0.00046 0.064  
Gamma-glutamylisoleucine Gamma-glutamyl amino acid 100 1.23 1.08, 1.41 0.0022 0.093  
Gamma-glutamylphenylalanine Gamma-glutamyl amino acid 100 1.20 1.05, 1.36 0.0070 0.14  
Abbreviations: OR = odds ratio, CI = confidence interval, s.d. = standard deviation, ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention, 
FDR = false discovery rate, ICD = International Classification of Diseases. 
a Metabolites with FDR (q-value) < 0.15 were included in the table.  
b Metabolites were log-transformed and standardized (mean = 0, s.d. = 1). All metabolites had detectable values in > 90% of the study population 
with the exception of dipeptides leucylglycine, histidylalanine, valylglycine, leucylglutamine, and eicosanoid 5-HEPE (38%, 25%, 51%, 39% and 
57%, respectively).  
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c Odds ratio per 1 s.d. increase in metabolite level based on 523 case-control pairs. Lethal prostate cancer was defined as cases who died of prostate 
cancer (ICD-9=185 or ICD-10=C61). Matching variables included age at blood collection (± 1 year), and date of baseline blood collection (± 30 
days). 
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Table 3. Gene-set analysis (GSA) and principal components analysis (PCA) for the association between chemical sub-classes of serum 
metabolites and lethal prostate cancer risk in the ATBC Study a 
Sub-class pathway No. of 
contributing 
metabolites 
GSA analysis PCA analysis 
P-value GSA q-value OR (95% CI) for 
pattern score b 
P-value q-value 
Overall lethal prostate cancer       
Dipeptide 9 <0.0001 <0.001 1.36 (1.17, 1.58) 5.8×10-5 0.0012 
Pyrimidine metabolism, uracil containing 10 <0.0001 <0.001 1.32 (1.16, 1.50) 3.7×10-5 0.0012 
Gamma-glutamyl amino acid 16 0.002 0.013 1.20 (1.05, 1.37) 0.0093 0.074 
Glycine, serine and threonine metabolism 9 0.006 0.029 1.10 (0.97, 1.25) 0.12 0.40 
Polyunsaturated fatty acid (n3 and n6) 14 0.008 0.031 1.17 (1.02, 1.33) 0.022 0.12 
Aminosugar metabolism 5 0.027 0.087 1.18 (1.03, 1.35) 0.017 0.12 
Androgenic steroids 21 0.033 0.092 1.08 (0.96, 1.21) 0.23 0.46 
Fatty acid, dicarboxylate 23 0.038 0.092 1.14 (1.004, 1.29) 0.044 0.17 
Endocannabinoid 11 0.049 0.10 1.16 (1.02, 1.33) 0.025 0.12 
       
Time to prostate cancer death c: 0-18 y        
Pyrimidine metabolism, uracil containing 10 0.001 0.031 1.35 (1.12, 1.64) 0.002 0.044 
Dipeptide 9 0.002 0.031 1.36 (1.13, 1.64) 0.001 0.044 
Fibrinogen cleavage peptide 5 0.006 0.055 0.78 (0.66, 0.93) 0.0060 0.052 
Glutathione metabolism 7 0.007 0.055 0.78 (0.65, 0.93) 0.0054 0.052 
Pyrimidine metabolism, cytidine 
containing 
5 0.015 0.094 0.77 (0.65, 0.93) 0.0049 0.052 
Gamma-glutamyl amino acid 16 0.022 0.10 1.20 (1.02, 1.41) 0.027 0.17 
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Polyunsaturated fatty acid (n3 and n6) 14 0.023 0.10 1.23 (1.02, 1.49) 0.029 0.17 
Fatty acid, dicarboxylate 23 0.033 0.13 1.19 (0.997, 1.43) 0.054 0.26 
       
Time to prostate cancer death c: >18 y       
Pyrimidine metabolism, uracil containing 10 0.008 0.32 1.29 (1.08, 1.54) 0.006 0.21 
Dipeptide 9 0.011 0.32 1.36 (1.06, 1.76) 0.017 0.30 
Aminosugar metabolism 5 0.077 0.94 1.20 (0.98, 1.47) 0.075 0.54 
Fibrinogen cleavage peptide 5 0.082 0.94 0.84 (0.68, 1.03) 0.099 0.54 
Histidine metabolism 14 0.14 0.94 1.12 (0.94, 1.33) 0.21 0.54 
Endocannabinoid 11 0.15 0.94 1.17 (0.96, 1.41) 0.12 0.54 
Abbreviations: OR = odds ratio, CI = confidence interval, s.d. = standard deviation, ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention, 
ICD = International Classification of Diseases. 
a Statistical significance of pathway analysis is defined as false discovery rate < 0.15 and P-value <0.05. The GSA Sub-class pathway analysis for 
overall lethal prostate cancer is based on 523 cases and 523 controls, for time to prostate cancer death (0-18 years) analysis is based on 263 cases 
and 263 controls. GSA and PCA q-value calculations are based on 59 tests.  
b Odds ratio per 1 s.d. increase in pattern score derived from PCA analysis (mean = 0, s.d. = 1). Lethal prostate cancer was defined as cases who 
died of prostate cancer (ICD-9=185 or ICD-10=C61). 
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Table 4. ORs and 95% CIs from conditional logistic regression for the association between cysteine related-metabolites (thioproline, cysteine, and 
cystine) and lethal prostate cancer risk in the ATBC Study 
Model Thioproline Cysteine Cystine  Thioproline, cysteine, and cystine a 
Crude model adjusting for matching factors    
Continuous     
Per s.d. 0.75 (0.65, 0.86) 0.80 (0.68, 0.93) 0.80 (0.70, 0.91) 0.71 (0.61, 0.83) 
P  8.2×10-5 0.004 0.0008 1.1×10-5 
     
Quartile categories    
First  1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent) 
Second 0.93 (0.65, 1.34) 0.81 (0.56, 1.18) 0.78 (0.55, 1.11) 0.77 (0.54, 1.10) 
Third 0.68 (0.47, 0.99) 0.63 (0.42, 0.93) 0.65 (0.45, 0.93) 0.67 (0.47, 0.96) 
Fourth 0.54 (0.37, 0.79) 0.57 (0.37, 0.87) 0.73 (0.51, 1.05) 0.53 (0.36, 0.78) 
P for trend b 0.0005 0.006 0.048 0.0011 
     
Multivariable-adjusted model c     
Continuous     
Per s.d. 0.73 (0.63, 0.85) 0.79 (0.67, 0.93) 0.78 (0.68, 0.90) 0.70 (0.59, 0.82) 
P 6.3×10-5 0.0038 0.0005 6.6×10-6 
     
Quartile categories     
First  1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent) 
Second 0.89 (0.61, 1.29) 0.83 (0.57, 1.21) 0.80 (0.56, 1.14) 0.76 (0.53, 1.09) 
Third 0.66 (0.45, 0.96) 0.64 (0.43, 0.96) 0.63 (0.43, 0.91) 0.63 (0.44, 0.92) 
Fourth 0.51 (0.34, 0.76) 0.56 (0.36, 0.87) 0.73 (0.50, 1.06) 0.50 (0.33, 0.75) 
P for trend b 0.0003 0.0055 0.039 0.0006 
Abbreviations: OR = odds ratio, CI = confidence interval, s.d. = standard deviation, ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention, 
ICD = International Classification of Diseases. 
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a The cysteine-related metabolite combination (thioproline, cysteine, and cystine) is modeled based on the formula: β1X1 + β2X2 + β3X3, Xj 
denoting the standardized value from the jth metabolite, and βj denoting the coefficient of the metabolite from regression model. Lethal prostate 
cancer was defined as cases who died of prostate cancer (ICD-9=185 or ICD-10=C61).  
b P for trend: the statistical significance of the coefficient of the quartile variable (median value within each quartile). 
c Model adjusting for matching factors, BMI, smoking, ATBC intervention group, and baseline serum total cholesterol, HDL cholesterol, alpha-
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Table 5. ORs and 95% CIs from unconditional logistic regression (per 1-s.d.) for the association between serum metabolites and lethal prostate 
cancer with distant metastasis at diagnosis in the ATBC Study (FDR<0.15) a  
Metabolite b Sub-class pathway OR c 95% CI P-value Q-value 
Amino acids and amino acid 
derivatives  
     
N-Acetylglycine Glycine, serine and threonine metabolism 1.37 1.14, 1.65 0.00065 0.083 
Pro-hydroxy-pro Urea cycle; arginine and proline 
metabolism 
1.32 1.10, 1.59 0.0025 0.13 
Lipids      
Pimeloylcarnitine/3-
methyladipoylcarnitine (C7-DC) 
Fatty acid metabolism (acyl carnitine) 1.40 1.15, 1.69 0.00066 0.083 
Suberoylcarnitine (C8-DC) Fatty acid metabolism (acyl carnitine) 1.37 1.13, 1.66 0.0013 0.11 
Adipoylcarnitine (C6-DC) Fatty acid metabolism (acyl carnitine) 1.32 1.11, 1.58 0.0020 0.13 
Hexanoylglycine Fatty acid metabolism (acyl glycine) 1.49 1.22, 1.83 0.000088 0.033 
3-Hydroxybutyroylglycine Fatty acid metabolism (acyl glycine) 1.40 1.16, 1.69 0.00037 0.083 
3-Methyladipate Fatty acid, dicarboxylate 1.40 1.16, 1.70 0.00048 0.083 
Hexadecenedioate (C16:1-DC) Fatty acid, dicarboxylate 1.34 1.12, 1.60 0.0013 0.11 
Suberate (C8-DC) Fatty acid, dicarboxylate 1.32 1.10, 1.59 0.0032 0.14 
3-Hydroxysebacate Fatty acid, monohydroxy 1.35 1.12, 1.64 0.0020 0.13 
3-Hydroxyoctanoate Fatty acid, monohydroxy 1.32 1.10, 1.59 0.0030 0.14 
3-Hydroxybutyrate (BHBA) Ketone bodies 1.46 1.22, 1.75 3.8×10-5 0.029 
Acetoacetate Ketone bodies 1.36 1.13, 1.64 0.0014 0.11 
1-Linoleoyl-GPC (18:2) Lysophospholipid 0.76 0.64, 0.91 0.0024 0.13 
Nucleotide      
2'-O-Methyluridine Pyrimidine metabolism, uracil containing 1.33 1.11, 1.58 0.0014 0.11 
Peptide      
Gamma-Glutamylglycine Gamma-glutamyl amino acid 1.36 1.11, 1.67 0.0028 0.14 
Abbreviations: OR = odds ratio, CI = confidence interval, s.d. = standard deviation, ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention, 
FDR = false discovery rate.  
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a Metabolites with FDR (q-value) < 0.15 were included in the table.  
b Metabolites were log transformed and standardized (mean = 0, s.d. = 1).  
c We used unconditional logistic regression models adjusted for age at blood collection, date of baseline blood collection, and time interval from 
blood collection to cancer diagnosis (or index date of their originally matched cases, for controls) to estimate odds ratio per 1-s.d. increase in 
metabolite level, on the basis of 179 M1 cases and 523 controls. Lethal cases with metastatic disease were defined as those with distant metastasis 
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Impaired metabolism may play an important role in the pathogenesis of lethal prostate 
cancer (LPC), but evidence remains scarce. This study examined the associations 
between serum metabolites and LPC risk years in advance of diagnosis using untargeted 
mass-spectrometry-based metabolomics. Increased oxidative stress-related thioproline 
and two other cysteine-related metabolites were prominently associated with lower LPC 
risk. By contrast, dipeptides including leucylglycine, and several gamma-glutamyl 
aminoacids, were related to elevated risk. This prospective molecular pattern points to a 
role for redox and peptide metabolism in LPC and provides potential leads regarding the 
molecular basis of its pathogenesis. 
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